Advertisement

Drugs

pp 1–11 | Cite as

Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy

  • Alexander C. Cohen
  • Brandon M. Roane
  • Charles A. LeathIIIEmail author
Leading Article

Abstract

While screening programs and HPV vaccination have decreased the incidence of cervical cancer, still over 13,000 cases occur in the USA annually. Early-stage cervical cancer has an excellent long-term prognosis, with 5-year survival for localized disease being > 90%. Survival decreases markedly for both locally advanced and metastatic disease, and both are associated with a higher risk of recurrence. Few effective treatment options exist for persistent, recurrent, or metastatic cervical cancer. In 2014, the anti-VEGF antibody bevacizumab was approved in combination with chemotherapy based on the results of the Phase III GOG-240 study. As the majority of cervical cancers have a viral etiology, which impairs the immune system, immunotherapy using checkpoint inhibitors and other agents, appears to be a promising approach. In June 2018, the US FDA approved the anti-PD1 antibody pembrolizumab for recurrent or metastatic cervical cancer with PD-L1 expression that progressed after one or more lines of chemotherapy. Another anti-PD1 antibody, cemiplimab also shows potential in this setting, either as monotherapy or combined with radiotherapy, and it is currently being evaluated in a Phase III trial. Additional checkpoint inhibitors including nivolumab, durvalumab, atezolizumab, and camrelizumab are in different stages of clinical development for the disease. Finally, an additional targeted approach being pursued involves PARP inhibitors (rucaparib and olaparib are both in Phase II) based on earlier study results.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript. CAL was supported in part by the UG1 CA23330 and P50 CA098252.

Conflict of interest

Alexander C. Cohen, Brandon M. Roane, and Charles A. Leath, III declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.  https://doi.org/10.3322/caac.21492.CrossRefGoogle Scholar
  2. 2.
    Lees BF, Erickson BK, Huh WK. Cervical cancer screening: evidence behind the guidelines. Am J Obstet Gynecol. 2016;214:438–43.  https://doi.org/10.1016/j.ajog.2015.10.147.CrossRefPubMedGoogle Scholar
  3. 3.
    Society, A.C. Key Statistics for Cervical Cancer. https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html. Accessed 29 July 2019.
  4. 4.
    U.S. Department of Health and Human Services, C.f.D.C.a.P.a.N.C.I. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016). http://www.cdc.gov/cancer/dataviz. Accessed 29 July 2019.
  5. 5.
    Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899–903.  https://doi.org/10.1002/1097-0142(19810815)48:4%3c899:aid-cncr2820480406%3e3.0.co;2-6.CrossRefPubMedGoogle Scholar
  6. 6.
    Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, Phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654–63.  https://doi.org/10.1016/s0140-6736(17)31607-0.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.  https://doi.org/10.1002/(sici)1096-9896(199909)189:1%3c12:Aid-path431%3e3.0.Co;2-f.CrossRefPubMedGoogle Scholar
  8. 8.
    Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;110:525–41.  https://doi.org/10.1042/cs20050369.CrossRefPubMedGoogle Scholar
  9. 9.
    Schiller JT, Castellsague X, Garland SMA. review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.  https://doi.org/10.1016/j.vaccine.2012.04.108.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4:e19–27.  https://doi.org/10.1016/s2468-2667(18)30183-x.CrossRefPubMedGoogle Scholar
  11. 11.
    Safaeian, M, Solomon, D, Castle, P.E. Cervical cancer prevention–cervical screening: science in evolution. Obstetrics and gynecology clinics of North America 2007, 34, 739-760, ix,  https://doi.org/10.1016/j.ogc.2007.09.004.CrossRefGoogle Scholar
  12. 12.
    Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, et al. Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: an ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecol Oncol. 2017;147:98–103.  https://doi.org/10.1016/j.ygyno.2017.07.121.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–904.  https://doi.org/10.1056/NEJMoa1806395.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu F, Wang Y, Xu Z, Qu H, Zhang H, Niu L, et al. Novel adenoassociated virusbased genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Mol Med Rep. 2019;19:1016–23.  https://doi.org/10.3892/mmr.2018.9739.CrossRefPubMedGoogle Scholar
  15. 15.
    Schmidt AM, Imesch P, Fink D, Egger H. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125:604–9.  https://doi.org/10.1016/j.ygyno.2012.03.001.CrossRefPubMedGoogle Scholar
  16. 16.
    Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33:2129–35.  https://doi.org/10.1200/jco.2014.58.4391.CrossRefPubMedGoogle Scholar
  17. 17.
    Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55.  https://doi.org/10.1200/jco.2009.21.8909.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113–9.  https://doi.org/10.1200/jco.2004.04.170.CrossRefPubMedGoogle Scholar
  19. 19.
    Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:922–8.  https://doi.org/10.1016/s0360-3016(03)00209-8.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20:660–73.  https://doi.org/10.1634/theoncologist.2014-0465.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.  https://doi.org/10.1200/jco.2005.06.081.CrossRefPubMedGoogle Scholar
  22. 22.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.  https://doi.org/10.1038/nm0603-669.CrossRefPubMedGoogle Scholar
  23. 23.
    Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000;96:721–6.PubMedGoogle Scholar
  24. 24.
    Minion LE, Tewari KS. Cervical cancer—state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018;148:609–21.  https://doi.org/10.1016/j.ygyno.2018.01.009.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pfaendler KS, Liu MC, Tewari KS. Bevacizumab in cervical cancer: 5 years after. Cancer J. 2018;24:187–92.  https://doi.org/10.1097/ppo.0000000000000324.CrossRefPubMedGoogle Scholar
  26. 26.
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27:1069–74.  https://doi.org/10.1200/jco.2008.18.9043.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Liu, F.W, Cripe, J, Tewari, K.S. Anti-angiogenesis therapy in gynecologic malignancies. Oncology (Williston Park, N.Y.). 2015;29:350–360.Google Scholar
  28. 28.
    Redondo A, Colombo N, Dreosti LM, McCormack M, Rodrigues AN, Donica M, et al. Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC). J Clin Oncol. 2018;36:5528.  https://doi.org/10.1200/JCO.2018.36.15_suppl.5528.CrossRefGoogle Scholar
  29. 29.
    Yamashita, H, Murakami, N, Asari, T, Okuma, K, Ohtomo, K, Nakagawa, K. Correlation among six biologic factors (p53, p21WAF1, MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. Int J Radiat Oncol Biol Phys. 2009;74:1165–1172.  https://doi.org/10.1016/j.ijrobp.2008.09.005.CrossRefGoogle Scholar
  30. 30.
    Pérez-Regadera J, Sánchez-Muñoz A, De-la-Cruz J, Ballestín C, Lora D, García-Martín R, et al. Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer. Oncology. 2009;76:133–41.  https://doi.org/10.1159/000195539.CrossRefPubMedGoogle Scholar
  31. 31.
    Monk BJ, Lopez LM, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–9.  https://doi.org/10.1200/jco.2009.26.9571.CrossRefPubMedGoogle Scholar
  32. 32.
    D’Souza A, Roman LD, Saura C, Braña I, Shapiro GI, Passalacqua R, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the Phase 2 SUMMIT trial. Gynecol Oncol. 2019;154:11.  https://doi.org/10.1016/j.ygyno.2019.04.033.CrossRefGoogle Scholar
  33. 33.
    Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled Phase 2 trial. Lancet Oncol. 2015;16:1515–24.  https://doi.org/10.1016/s1470-2045(15)00220-x.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121:303–8.  https://doi.org/10.1016/j.ygyno.2011.01.030.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mackay, H.J, Tinker, A, Winquist, E, Thomas, G, Swenerton, K, Oza, A, et al. A Phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116:163–167.  https://doi.org/10.1016/j.ygyno.2009.08.012.CrossRefGoogle Scholar
  36. 36.
    Evaluate efficacy of the association nimotuzumab(HR3)/cisplatin-vinorelbine on patients with cervical carcinom (CIMAHOPE). https://ClinicalTrials.gov/show/NCT03413579.
  37. 37.
    Study of nimotuzumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer. https://ClinicalTrials.gov/show/NCT03469531.
  38. 38.
    ENGOT-cx1/BGOG-cx1: 3 weekly carboplatin/paclitaxel with or without nintedanib in cervix cancer. https://ClinicalTrials.gov/show/NCT02009579.
  39. 39.
    Apatinib and chemotherapy sequential treatment with cervical cancer. https://ClinicalTrials.gov/show/NCT03029013.
  40. 40.
    Rabenau K, Hofstatter E. DNA damage repair and the emerging role of poly(ADP-ribose) polymerase inhibition in cancer therapeutics. Clin Ther. 2016;38:1577–88.  https://doi.org/10.1016/j.clinthera.2016.06.006.CrossRefPubMedGoogle Scholar
  41. 41.
    Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.  https://doi.org/10.1126/science.aam7344.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Liu FW, Tewari KS. New targeted agents in gynecologic cancers: synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Opt Oncol. 2016;17:12.  https://doi.org/10.1007/s11864-015-0378-9.CrossRefGoogle Scholar
  43. 43.
    Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.  https://doi.org/10.3389/fonc.2013.00237.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer Lett. 1981;14:227–36.  https://doi.org/10.1016/0304-3835(81)90148-8.CrossRefPubMedGoogle Scholar
  45. 45.
    Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, et al. A Phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017;28:505–11.  https://doi.org/10.1093/annonc/mdw635.CrossRefPubMedGoogle Scholar
  46. 46.
    Kunos C, Deng W, Dawson D, Lea JS, Zanotti KM, Gray HJ, et al. A Phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer. 2015;25:484–92.  https://doi.org/10.1097/IGC.0000000000000380.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. https://ClinicalTrials.gov/show/NCT03476798.
  48. 48.
    Study of niraparib with radiotherapy for treatment of metastatic invasive carcinoma of the cervix. https://ClinicalTrials.gov/show/NCT03644342.
  49. 49.
    Mittica G, Genta S, Aglietta M, Valabrega G. Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int J Mol Sci. 2016;17:1169.  https://doi.org/10.3390/ijms17071169.CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.  https://doi.org/10.1186/s40661-016-0033-6.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.  https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.  https://doi.org/10.1016/j.ccell.2015.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kumar L, Harish P, Malik PS, Khurana S. Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer. 2018;42:120–8.  https://doi.org/10.1016/j.currproblcancer.2018.01.016.CrossRefPubMedGoogle Scholar
  54. 54.
    Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, Wang HW. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstetr Gynaecol Res. 2017;43:1602–12.  https://doi.org/10.1111/jog.13411.CrossRefGoogle Scholar
  55. 55.
    Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. 2019;37:1470–1478.  https://doi.org/10.1200/jco.18.01265.CrossRefGoogle Scholar
  56. 56.
    Broderick J. Pembrolizumab granted FDA approval for PD-L1 + cervical cancer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s034lbl.pdf. Accessed 4 Aug.
  57. 57.
    Efficacy and safety study of first-line treatment with pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer (MK-3475-826/KEYNOTE-826). https://ClinicalTrials.gov/show/NCT03635567.
  58. 58.
    Pembrolizumab and chemoradiation treatment for advanced cervical cancer. https://ClinicalTrials.gov/show/NCT02635360.
  59. 59.
    Drugs.com. Opidivo approval history. https://www.drugs.com/history/opdivo.html. Accessed 14 Aug.
  60. 60.
    Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II checkmate 358 trial. J Clin Oncol. 2019;37(31):2825–34.  https://doi.org/10.1200/JCO.19.00739.CrossRefPubMedGoogle Scholar
  61. 61.
    Naumann RW, O.A., Meyer T, et al. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358. In: Proceedings of European society for medical oncology, Barcelona, Spain, September 27–October 2, 2019.Google Scholar
  62. 62.
    Nivolumab in treating patients with persistent, recurrent, or metastatic cervical cancer. https://ClinicalTrials.gov/show/NCT02257528.
  63. 63.
    Study of REGN2810 in adults with cervical cancer. https://ClinicalTrials.gov/show/NCT03257267.
  64. 64.
    Platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab in metastatic carcinoma of the cervix. https://ClinicalTrials.gov/show/NCT03556839.
  65. 65.
    Trial assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint atezolizumab. https://ClinicalTrials.gov/show/NCT03612791.
  66. 66.
    Atezolizumab before and/or with chemoradiotherapy in immune system activation in patients with node positive stage IB2, II, IIIB, or IVA cervical cancer. https://clinicaltrials.gov/ct2/show/NCT03738228.
  67. 67.
    Avelumab with valproic acid in virus-associated cancer. https://ClinicalTrials.gov/show/NCT03357757.
  68. 68.
    Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy. https://ClinicalTrials.gov/show/NCT03826589.
  69. 69.
    Study of durvalumab with chemoradiotherapy for women with locally advanced cervical cancer (CALLA). https://ClinicalTrials.gov/show/NCT03830866.
  70. 70.
    Stereotactic body radiation therapy, tremelimumab and durvalumab in treating participants with recurrent or metastatic cervical, vaginal, or vulvar cancers. https://ClinicalTrials.gov/show/NCT03452332.
  71. 71.
    Chemoradiation therapy and ipilimumab in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. https://ClinicalTrials.gov/show/NCT01711515.
  72. 72.
    Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 combined with immune therapies in advanced or metastatic malignancies. https://ClinicalTrials.gov/show/NCT03126110.
  73. 73.
    A study exploring the safety and efficacy of INCAGN01949 in combination with immune therapies in advanced or metastatic malignancies. https://ClinicalTrials.gov/show/NCT03241173.
  74. 74.
    Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8:421–39.  https://doi.org/10.1517/14712598.8.4.421.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Yang A, Farmer E, Wu TC, Hung C-F. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23:75.  https://doi.org/10.1186/s12929-016-0293-9.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Yang A, Jeang J, Cheng K, Cheng T, Yang B, Wu TC, Hung CF. Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vacc. 2016;15:989–1007.  https://doi.org/10.1586/14760584.2016.1157477.CrossRefGoogle Scholar
  77. 77.
    Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Alcocer-Gonzalez JM, Tamez-Guerra RS, de Oca-Luna RM, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol. 2004;53:427–33.  https://doi.org/10.1099/jmm.0.05472-0.CrossRefPubMedGoogle Scholar
  78. 78.
    Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13:89–98.  https://doi.org/10.1080/10611860400024219.CrossRefPubMedGoogle Scholar
  79. 79.
    Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26:5315–20.  https://doi.org/10.1016/j.vaccine.2008.07.036.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Peters C, Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine. 2003;21:1187–94.  https://doi.org/10.1016/s0264-410x(02)00554-6.CrossRefPubMedGoogle Scholar
  81. 81.
    Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S, et al. Randomized phase 2 study of ADXS11-001 listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018;28:764–72.  https://doi.org/10.1097/IGC.0000000000001235.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Huh W, Brady WE, Dizon DS, Powell MA, Landrum LM, Leath CA III, et al. A prospective Phase II trial of the listeria-based human papillomavirus immunotherpay axalimogene filolisbac in second- and third-line metastatic cervical cancer: a NRG oncology group trial. Gynecol Oncol. 2017;145:220.  https://doi.org/10.1016/j.ygyno.2017.03.506.CrossRefGoogle Scholar
  83. 83.
    ADXS11-001 high dose HPV + cervical cancer. https://ClinicalTrials.gov/show/NCT02164461.
  84. 84.
    Kim TJ, Jin H-T, Hur S-Y, Yang HG, Seo YB, Hong SR, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.  https://doi.org/10.1038/ncomms6317.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    The combination of GX-188E vaccination and pembrolizumab in patients with HPV 16 and/or 18 + cervical cancer. https://ClinicalTrials.gov/show/NCT03444376.
  86. 86.
    Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254–62.  https://doi.org/10.1016/s1470-2045(16)30030-4.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Jerjian TV, Glode AE, Thompson LA, O’Bryant CL. Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy. Pharmacotherapy. 2016;36:99–116.  https://doi.org/10.1002/phar.1687.CrossRefPubMedGoogle Scholar
  88. 88.
    Zhao X, Cheng C, Gou J, Yi T, Qian Y, Du X, Zhao X. Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med. 2018;16:4075–81.  https://doi.org/10.3892/etm.2018.6723.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Nejadmoghaddam M-R, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani A-H. Antibody-drug conjugates: possibilities and challenges. Avicenna J Med Biotechnol. 2019;11:3–23.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Tisotumab vedotin (HuMax®-TF-ADC) safety study in patients with solid tumors. https://ClinicalTrials.gov/show/NCT02001623.
  91. 91.
    A trial of tisotumab vedotin in cervical cancer. https://ClinicalTrials.gov/show/NCT03438396.
  92. 92.
    Safety and efficacy of tisotumab vedotin in combination with other cancer agents in subjects with cervical cancer. https://ClinicalTrials.gov/show/NCT03786081.
  93. 93.
    de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, Phase 1-2 trial. Lancet Oncol. 2019;20:383–93.  https://doi.org/10.1016/s1470-2045(18)30859-3.CrossRefPubMedGoogle Scholar
  94. 94.
    Mayor P, Starbuck K, Zsiros E. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol. 2018;150:361–9.  https://doi.org/10.1016/j.ygyno.2018.05.024.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyO’Neal Comprehensive Cancer Center, University of Alabama at BirminghamBirminghamUSA

Personalised recommendations